A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918588 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune System Disorder (Healthy Volunteer)

Interventions

DRUG: Belumosudil mesylate
DRUG: Placebo

Sponsor

Kadmon, a Sanofi Company